TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03648515

Intervention type: DIAGNOSTIC_TEST
Intervention: Plaster models
Description: The impressions taken of the dental arches will be poured with hard gypsum in order to make use of the models for taking measurements. These measurements will be considered the gold standard.

Intervention type: DIAGNOSTIC_TEST
Intervention: Digital Images of the dental arches
Description: The dental arches will be captured using a dedicated camera in order to be used for measuring the outcomes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Digital images of models
Description: The poured dental models will be captured using a dedicated camera in order to be used for measuring the outcomes.
Study: NCT04331717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bead Block 300-500 um
Description: These patients will undergo embolization with 300-500µm Bead Block particles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Management
Description: All participants will be enrolled in weight management through the Johns Hopkins Weight Management Center. During weeks -4 through 0, participants will be required to go to weekly visits. Weight management will include counseling on diet, exercise and behavior change. Food programs, pharmacotherapy and other procedures will not be utilized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lupron
Description: 22.5 mg will be given as a single intramuscular or subcutaneous injection once every 12 weeks according to the standard of care for prostate cancer. If leuprolide acetate, 22.5 mg for 3-month administration is not available, a suitable substitute may be allowed upon approval by the principle investigator
Study: NCT03301207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam 2 mg (1 milliliter \[mL\]) oral solution will be taken on Study Days 3 and 24 (as a part of CYP cocktail) and on Study Day 8 (alone).
Study: NCT04752007

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: ASLR; CT; SI joint movement: stright leg raise with 1 kg load
Description: Measurement of the SI joint movement in mikrometer

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Fig.Four; CT; SI joint movement: One side figure of four position with 1 kg load
Description: Measurement of the SI joint movement in mikrometer
Study: NCT04488029

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Workbooks
Description: Subjects in this group will be provided with a standard regime of paper workbooks (e.g. Workbook for Aphasia: Exercises for Expressive and Receptive Language Functioning; Brubaker, 2006) that are typically used by clinicians to practice therapy tasks with individuals. Notably, the control procedure employed here is similar to that employed on a large-scale study examining technology as a treatment option and involved usual care control group by Palmer and colleagues (2015).
Study: NCT01615614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: Type=exact number, unit=mg, number=150, form=capsule, route=oral. Two capsules daily will be administered for 17 days.
Study: NCT02133131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir/Elbasvir FDC
Description: FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken q.d. by mouth.
Study: NCT03251937

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectra WaveWriter SCS System
Description: Multiple modalities of stimulation therapy
Study: NCT01224717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTH134

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Forsteo
Study: NCT02133131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir/Elbasvir FDC
Description: FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir/Elbasvir FDC
Description: FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken q.d. by mouth.
Study: NCT02630472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinine Sulfate
Description: Our plan is to first study quinine against saline to determine efficacy and safety. The vast majority of patients with rhinosinusitis utilize low pressure / high volume (240mls) sinonasal lavage to cleanse the sinonasal cavity. The patients will be exposed to a maximum of 12mls or 12.0 mg of quinine. In standard tonic water, quinine is 8.3mg/100mls and thus an 8oz glass of Canada Dry tonic water has 19.6mg of quinine. Thus, the maximum systemic exposure in our study (assuming ingestion of the total nasal administration) is less than drinking one glass of tonic water / day. To put this in context, the therapeutic range of quinine to treat malaria is 10mg/kg true ileal digestibility (TID) (2100mg for a 70kg individual) nearly 200 X the dose the investigators are proposing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In order to blind the participants to which arm they have been randomized into, the placebo arm will contain saline solution spiked with 0.5 mg/ml sucrose octaacetate. This solution will produce a bitter flavor similar to the one produced by quinine. There is no evidence that sucrose octaacetate produces nitric oxide production in the sinonasal cavity, nor is there evidence that it has any side effects (it is used to wean babies off of pacifiers) so the investigators feel it is an effective and safe option for a placebo.
Study: NCT01136408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Dabigatran etexilate 110 mg capsule, twice a day, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Dabigatran etexilate 150 mg capsule, twice a day, oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Dose-adjusted warfarin based on target INR values
Study: NCT02306798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP05
Description: One radio-labelled tablet given to subject after a high fat and a rich in calories breakfast
Study: NCT01912196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSI-195

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03496675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Music Therapy
Description: The core intention of GMT is to meet the psychosocial needs of each person living with dementia, which in turn is thought to reduce depressive symptoms and anxiety and to stimulate overall social and emotional wellbeing. It includes active, reciprocal music making with the use of singing and musical instruments. GMT is provided by a trained music therapist, highly skilled as a musician, and registered with the appropriate professional association in his or her country.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Music Therapy
Description: The core intention of GMT is to meet the psychosocial needs of each person living with dementia, which in turn is thought to reduce depressive symptoms and anxiety and to stimulate overall social and emotional wellbeing. It includes active, reciprocal music making with the use of singing and musical instruments. GMT is provided by a trained music therapist, highly skilled as a musician, and registered with the appropriate professional association in his or her country.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recreational Choir Singing
Description: RCS is intended to foster connectedness in a group, wellbeing, and enjoyment of music making in a group. It includes singing familiar songs and providing a familiar musical environment for participants. RCS is provided by a musician with choir leading skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recreational Choir Singing
Description: RCS is intended to foster connectedness in a group, wellbeing, and enjoyment of music making in a group. It includes singing familiar songs and providing a familiar musical environment for participants. RCS is provided by a musician with choir leading skills.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: May include pharmacological and non-pharmacological interventions as locally available

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: May include pharmacological and non-pharmacological interventions as locally available

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: May include pharmacological and non-pharmacological interventions as locally available

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: May include pharmacological and non-pharmacological interventions as locally available
Study: NCT02034877

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal conjugate vaccine
Description: 1 dose (0.5 mL/ pre-filed syringe) of 13vPnC administered at visit 1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample collection
Description: 10 mL of blood will be collected just before and approximately 1 month after vaccination.
Study: NCT01423292

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound Guided Transversus Abdominis Plane (TAP) Block
Description: Ultrasound Guided Transversus Abdominis Plane (TAP) Block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Transversus Abdominis Plane (TAP) Block
Description: Ultrasound Guided Transversus Abdominis Plane (TAP) Block
Study: NCT04752007

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Supine; CT; SI joint movement: supine position
Description: Baseline position
Study: NCT01423292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: 0.25 bupivacaine 30ml (15ml on each side)
Study: NCT01423292

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT01980381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tree Theme Method ® (TTM)
Description: The TTM method is based on creative activities and occupational life story telling, implies that the paints trees representing different life periods, looking back and forward, as well as the present.
Study: NCT04656743

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intra-articular injection
Description: The injection will be performed under ultrasound guidance by placing the patient's knee in approximately 90° of flexion with the leg hanging off the side of the bed (left). A high-frequency linear transducer ultrasound probe is placed in the superolateral corner of the patella, directed medially toward the patellofemoral joint space. In the extended leg, from anterior to posterior, the right image shows the quadriceps femoris tendon (QF), suprapatellar fat pad (SF), suprapatellar bursa (SB), prefemoral fat pad (PF), and femur (F). When the knee is flexed to 90°, the size of the suprapatellar bursa image is increased. Using an in-plane approach, the needle will be directed into the suprapatellar joint space, and 20 ml of bupivacaine 0.25% will be injected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: genicular nerve block
Description: The transducer will be first placed parallel to the long bone shaft and moved up or down to identify the epicondyle of the long bone. The genicular arteries will be identified near the periosteal areas, confirmed by color Doppler ultrasound. Accordingly, genicular nerve block target points should be next to each genicular artery. After using color Doppler to confirm the genicular artery, the needle will be inserted in the plane of the ultrasound probe in the long-axis view. a gentle aspiration will be performed and a 2 mL injection volume will be administered.
Study: NCT02682732

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT guided bone marrow sampling
Description: (Fluorodeoxyglucose positron-emission tomography) FDG-PET/CT guided bone marrow sampling will be used to obtain two different samples from avid and dim bone marrow areas.
Study: NCT05504044

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose control
Description: 50 g glucose dissolved in 250 mL water

Intervention type: OTHER
Group type: OTHER
Intervention: Bread control
Description: 91.4 g white bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond paste
Description: 88.7 g white bread and 15 g almond paste

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond paste and inulin
Description: 88.7 g white bread, 15 g almond paste and 4 g inulin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low dose almond paste and inulin
Description: 89.6 g white bread, 10 g almond paste and 3.8 g inulin
Study: NCT03524014

Intervention type: OTHER
Intervention: Only advice for diagnosis and prevention
Description: Only advice for diagnosis and prevention
Study: NCT02474199

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: darTregs
Description: A single intravenous infusion as described administered over a 20-30 minute interval with close monitoring prior to, during, and after the infusion.
Study: NCT04752007

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: ASLR; RSA; SI joint movement: stright leg raise with 1 kg load
Description: Measurement of the SI joint movement in mikrometer

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Fig.Four; RSA; SI joint movement: One side figure of four position with 1 kg load
Description: Measurement of the SI joint movement in mikrometer

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Supine; RSA; SI joint movement: supine position
Description: Baseline position
Study: NCT00591552

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Harmonic ACE23P Scalpel
Description: Lymph node dissection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocautery
Study: NCT01582711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Administered Therapy (SAT)
Description: Self Administered Therapy (SAT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Administered Therapy (SAT)
Description: Self Administered Therapy (SAT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS reminders
Description: Short Message Service (SMS) text reminders

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isoniazid and rifapentine
Description: rifapentine (PRIFTIN, RPT) 900 mg and isoniazid (INH) 900mg, once-weekly, for 12 weeks (12 doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazid and rifapentine
Description: rifapentine (PRIFTIN, RPT) 900 mg and isoniazid (INH) 900mg, once-weekly, for 12 weeks (12 doses)
Study: NCT02474199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Pre-medication for darTregs infusion. A dose of 15 mg/kg will be administered 30 to 60 minutes prior to the darTregs infusion.
Study: NCT01582711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazid and rifapentine
Description: rifapentine (PRIFTIN, RPT) 900 mg and isoniazid (INH) 900mg, once-weekly, for 12 weeks (12 doses)
Study: NCT03329092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATM-AVI
Description: (Creatinine clearance \> 50 mL/min) 6500 mg ATM/2167 mg (loading dose, extended loading dose and maintenance dose) by iv infusion on Day 1 followed by a total daily dose of 6000 mg ATM/2000 mg AVI~(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1417 mg AVI on Day 1 (loading dose, extended loading dose, maintenance dose) followed by total daily dose 3000 mg ATM/1000 mg AVI~(Creatinine clearance 16 - 30 mL/min) 2700 mg ATM/900 mg AVI on Day 1 (loading dose, extended loading dose maintenance dose), followed by total daily dose 2025 mg ATM/675 mg AVI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTZ
Description: For cIAI only; 500 mg/100 mL metronidazole iv infusion over 1hr q8h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MER
Description: Where pathogen initially not suspected of being MER-resistant:~(Creatinine clearance \> 50 mL/min) 1000 mg meropenem by 30 min iv infusion q8h~(Creatinine clearance 26 - 50 mL/min) 1000mg meropenem by 30 min iv infusion q12h~(Creatinine clearance 16 - 25 mL/min) 500 mg meropenem by 30 min iv infusion q12h~Where pathogen initially suspected of being MER-resistant (Creatinine clearance \> 50 mL/min) 2000 mg meropenem by 180 min iv infusion q8h~(Creatinine clearance 26 - 50 mL/min) 2000 mg meropenem by 180 min iv infusion q12h~(Creatinine clearance 16 - 25 mL/min) 1000 mg meropenem by 180 min iv infusion q12h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COL
Description: Loading dose 9 million IU by 30 -60 min iv infusion (6 million IU where weight \< 60 kg) followed by one of the following maintenance doses:~(Creatinine clearance \> 50 mL/min) after a 12h interval, commence maintenance dosing 9 million IU daily in 2 or 3 divided doses by 30 -60 min iv infusions.~(Creatinine clearance 31 - 50 mL/min) After a 24 hr interval, commence maintenance dosing of 6 million IU daily in 2 divided doses by 30 -60 min iv infusion~(Creatinine clearance 21 - 30 mL/min) After a 24 hr interval, commence maintenance dosing 5 million IU daily in 2 divided doses by 30 -60 min iv infusion~(Creatinine clearance 16 - 20 mL/min) after a 24 hr interval, commence maintenance dosing 4 million IU daily in 2 divided doses by 30 -60 min iv infusion
Study: NCT00783614

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 325mg
Description: Patients randomized to Aspirin 325mg po daily versus placebo pill daily
Study: NCT02474199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Pre-medication for darTregs infusion. A dose of 1-2 mg/kg diphenhydramine will be administered 30 to 60 minutes prior to the darTregs infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppression (IS) Withdrawal
Description: Subjects:1.) who fulfill study eligibility criteria will withdraw IS 2.) enter the study on calcineurin inhibitor (CNI) monotherapy or a CNI-based regimen with either Prednisone or MMF as a second IS medication 3.) will proceed with changes in CNI dosing according to the protocol's CNI withdrawal algorithm.During the last 2 weeks of IS withdrawal (e.g., Step 2 in algorithm -CNI reduced 25%-pre darTregs), a single dose of darTregs will be infused IV. The subject will then, if eligible, proceed with IS withdrawal within 2 weeks after the infusion. Eligible subjects meeting the primary endpoint of 75% reduction in CNI from baseline after darTregs will be offered the opportunity to continue IS withdrawal until complete discontinuation of IS.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Study Mandated Procedures
Description: Blood draws (venipuncture); collection of peripheral blood mononuclear cells (PBMCs) by a procedure known as leukapheresis or venipuncture; buccal (cheek) swab for HLA typing; liver biopsies (per protocol and for cause).
Study: NCT02404311

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALVAC-HIV
Description: a lyophilized vaccine for injection at a viral titer ≥ 1 × 10E6 cell culture infectious dose (CCID)50 and \< 1 × 10E8 CCID50 (nominal dose of 10E7 CCID50) and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALVAC-HIV
Description: a lyophilized vaccine for injection at a viral titer ≥ 1 × 10E6 cell culture infectious dose (CCID)50 and \< 1 × 10E8 CCID50 (nominal dose of 10E7 CCID50) and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent Subtype C gp120/MF59®
Description: 2 recombinant monomeric proteins, each at a dose of 100 mcg, mixed with MF59® adjuvant (an oil-in-water emulsion) delivered as a 0.5 mL IM injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent Subtype C gp120/MF59®
Description: 2 recombinant monomeric proteins, each at a dose of 100 mcg, mixed with MF59® adjuvant (an oil-in-water emulsion) delivered as a 0.5 mL IM injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent Subtype C gp120/MF59®
Description: 2 recombinant monomeric proteins, each at a dose of 100 mcg, mixed with MF59® adjuvant (an oil-in-water emulsion) delivered as a 0.5 mL IM injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ALVAC-HIV (vCP2438) Placebo
Description: a sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for injection as a single dose IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALVAC-HIV (vCP2438) Placebo
Description: a sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for injection as a single dose IM

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ALVAC-HIV (vCP2438) Placebo
Description: a sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for injection as a single dose IM

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Bivalent gp120/MF59® Placebo
Description: Sodium chloride for injection, 0,9% delivered as a 0.5 mL IM injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Bivalent gp120/MF59® Placebo
Description: Sodium chloride for injection, 0,9% delivered as a 0.5 mL IM injection
Study: NCT01542515

Intervention type: PROCEDURE
Intervention: Meniscal allograft arthroplasty of the carpometacarpal joint of the thumb
Description: The surgical procedure will involve the use of human meniscal allograft tissue that will be provided by industry. The meniscus will be contoured into a T shape. The T-shaped meniscus allograft is then inserted into the arthritic thumb CMC joint and secured with two suture anchors.
Study: NCT03106207

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Upper gastric endoscopy (UGE)
Description: UGE will be performed before the gastric bypass surgery and post-surgery at two, six and 12 months of clinical visit.
Study: NCT03479866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: To carry out an interventional dietary study using standardised meals to predict for an individual their metabolic response to certain foods using the gut microbiome and their metabolic profile. Responses will include post-prandial appetite, levels of satiety, circulating glucose, insulin, ketone bodies and lipid levels.